BSP Pharmaceuticals vs Piramal Pharma Solutions: CDMO Comparison
How does BSP Pharmaceuticals compare to Piramal Pharma Solutions for Biologics manufacturing?
Side-by-side comparison of BSP Pharmaceuticals and Piramal Pharma Solutions on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Piramal Pharma Solutions has more FDA inspections on record (7 vs 1) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- BSP Pharmaceuticals has materially broader EMA GMP coverage (15 active certificates vs 1) — stronger EU footprint.
- Piramal Pharma Solutions maintains 14 MHRA / UK GMP certificates; BSP Pharmaceuticals does not.
On a 13-modality CDMO landscape, both BSP Pharmaceuticals and Piramal Pharma Solutions qualify as Biologics manufacturers; Piramal Pharma Solutions carries the higher composite Signal Score for Biologics programs in this comparison.
What to evaluate for Biologics programs
Both BSP Pharmaceuticals and Piramal Pharma Solutions qualify as Biologics CDMOs. When choosing between them for Biologics programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
Frequently asked: BSP Pharmaceuticals vs Piramal Pharma Solutions
How does BSP Pharmaceuticals compare to Piramal Pharma Solutions for Biologics manufacturing?
On CDMO Signal's composite Signal Score, BSP Pharmaceuticals is 78/100 and Piramal Pharma Solutions is 84/100; BSP Pharmaceuticals has 1 FDA inspection on record vs 7 for Piramal Pharma Solutions; European coverage is 15 active EMA+MHRA certificates for BSP Pharmaceuticals vs 15 for Piramal Pharma Solutions. Both are tracked in the CDMO Signal directory as Biologics CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, BSP Pharmaceuticals or Piramal Pharma Solutions?
Both BSP Pharmaceuticals and Piramal Pharma Solutions maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. BSP Pharmaceuticals has 1 FDA inspection on record; Piramal Pharma Solutions has 7.
How do BSP Pharmaceuticals and Piramal Pharma Solutions compare on European GMP coverage?
BSP Pharmaceuticals holds 15 active EMA GMP certificates and 0 MHRA / UK certificates. Piramal Pharma Solutions holds 1 active EMA GMP certificate and 14 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for Biologics manufacturing — BSP Pharmaceuticals or Piramal Pharma Solutions?
Both BSP Pharmaceuticals and Piramal Pharma Solutions are tagged as Biologics CDMOs in our directory, so both are credible options for Biologics programs. The most important differentiator for Biologics selection is typically scale & bioreactor fit: Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
BSP Pharmaceuticals carries a Signal Score of 78/100 and Piramal Pharma Solutions carries 84/100 — a small lead for Piramal Pharma Solutions. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →